Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Santhosh A UpadhyayaOlivia CampagneCatherine A BillupsBrent A OrrArzu Onar-ThomasRuth G TatevossianRoya MostafaviJason R MyersAnna VinitskyDaniel C MoreiraHolly B LindsayLindsay KilburnPatricia BaxterAmy SmithJohn R CrawfordSonia PartapAnne E BendelDolly G AguileraKim E NicholsEvadnie RampersaudDavid W EllisonPaul KlimoZoltan PatayGiles W RobinsonAlberto BroniscerClinton F StewartCynthia WetmoreAmar GajjarPublished in: Neuro-oncology (2022)
Although the study did not meet pre-determined efficacy end point, single agent alisertib was well tolerated by children with recurrent AT/RT, and SD or PR was observed in approximately a third of the patients.